Dr. Lee will oversee the clinical development of Lycia’s lead programs, LCA-0061 for IgE-mediated diseases and LCA-0321 for ...
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we ...
Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets. The pharma ...
Lycia Therapeutics Inc. has reported progress in its immunology pipeline that comprises lysosomal targeting chimera (LYTAC)-based protein degradation therapies. The company is advancing its two lead ...
Hosted on MSN1mon
Video: Alabama Barker & Bestie Lycia Lamini Pop Out In The Drop-Top Corvette In Calabasas, CAWatch on LiveTube Now 👉 Video: Alabama Barker & Bestie Lycia Lamini Pop Out In The Drop-Top Corvette In Calabasas, CA #AlabamaBarker & Bestie #LyciaLamini Pop Out In The Drop-Top Corvette In ...
Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback